VivoSeq
Other

Habitual Abortion

8

Pipeline Programs

0

Active Trials

7

Companies Involved

Habitual Abortion is an early-stage landscape with 8 programs across 7 companies. The most active players are Iovance Biotherapeutics, Inc., Solvay Pharmaceuticals, Alnylam Pharmaceuticals. 3 therapies are approved with 2 more in late-stage development.

Pipeline Metrics

Competitive Density

33/100

Pipeline Velocity

0/100

Mech. Concentration

14/100

Completion Rate

100/100

Attrition Rate

0/100

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Programs by Phase

Modality Breakdown

89%

Small molecule

8 of 9 classified programs — the dominant modality here.

11%ALL OTHERSProtein / enzyme111%

Small molecule leads; the ring shows all 9 classified programs, each share of the total. Modality classified for 100% of 9 pipeline programs.

Trial Status

2

clinical trials

Completed2 · 100%

Trial Activity

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)